Efficacy and Biomarker Explanation on Resectable Non-Small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to explore the efficacy and biomarker explanation on resectable Non-Small Cell Lung Cancer who treated with Atezolizumab plus platinum based chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hunan Province Tumor Hospital
• Treatments: Atezolizumab

Criteria

Inclusion Criteria:

• Pathology revealed Non-Small Cell Lung Cancer and Driver gene negative

• Stage IIA-IIIA

• Patients who treated with Atezolizumab plus platinum based chemotherapy

Exclusion Criteria:

• Patients with contraindication of chemotherapy Pregnant or breast feeding women